Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab
Kommoss, Stefan , Winterhoff, Boris , Wang, C, Canzler, Ulrich , Aliferis, Constantin , Belau, Antje , Wang, Junli , Hanker, Lars , Ma, Sisi , Kimmig, Rainer , Tourani, Roshan , Kurzeder, Christian , Mahner, Sven� , Park-Simon, TW, Dowdy, SC, Pfisterer, Jacobus , Heitz, Florian , Kommoss, Felix , Bois, Andreas du , Ma, Sisi , Sehouli, Jalid

Mayo Clinic

Geburtshilfe und Frauenheilkunde | October 29, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0038-1671332 Get It

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease
Litzow, Mark R. , Wang, Xin V., Karp, Judith E. , Zhang, Yanming , Luger, Selina M. , Paietta, Elisabeth , Pratz, Keith W. , Altman, Jessica K. , Broun, E. Randolph, Rybka, Witold B. , Rowe, Jacob M. , Tallman, Martin S. , Kaufmann, Scott H. , Pratz, Keith W , Tun, Han Win, Carroll, Martin P , Ketterling, Rhett P. , Lazarus, Hillard M. , Tun, Han W.

Mayo Clinic

American Journal of Hematology | October 29, 2018 | Volume: 94 | Issue: 1 | Pages: 111-117

10.1002/ajh.25333 | PMID 30370956 Get It

To improve the outcome of relapsed/refractory acute myeloid leukemia (AML), a randomized phase II trial of three novel regimens was conducted. Ninety patients were enrolled and were in first relapse or were refractory to induction/re‐induction chemotherapy. They were randomized to the following regimens: carboplatin‐topotecan (CT), each by continuous infusion for 5 days; alvocidib (formerly flavopiridol), cytarabine, and mitoxantrone (FLAM) in a timed sequential regimen; or sirolimus combined with mitoxantrone, etoposide, and cytarabine (S‐MEC). The primary objective was attainment of a complete remission (CR). A Simon two‐stage design was used for each of the three arms. The median age of the patients in the FLAM arm was older at 62 years compared with 55 years for the CT arm and the S‐MEC arm. The overall response was 14% in the CT arm (5/35, 90% CI 7%‐35%), 28% in the FLAM arm (10/36, 90% CI, 16%‐43%), and 16% in the S‐MEC arm (3/19, 90% CI, 4%‐36%). There were nine treatment‐related deaths, seven of which occurred in the FLAM arm with four of these in elderly patients. We conclude that the FLAM regimen had an encouraging response rate and should be considered for further clinical development but should be used with caution in elderly patients.
Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer
Liao, Lili, Langbein, Lauren , Cho, Eun-Ah , Niu, Xiaohua , Jiang, Wei , Zhong, Zhijiu , Cai, Wesley L. , Jagannathan, Geetha , Dulaimi, Essel, Testa, Joseph R. , Uzzo, Robert G. , Wang, Yuxin , Stark, George R. , Peiper, Stephen C., Yan, Qin , Yang, Haifeng , Langbein, Lauren , Na, Jie , Xu, Yaomin , Yan, Qin , Yang, Haifeng , Liu, Zongzhi Z. , Cai, Weijia , Na, Jie, Sun, Jianxin

Mayo Clinic

eLife | October 25, 2018 | Volume: 7 | Issue: No issue available | Pages: No page available

10.7554/elife.37925 | PMID 30355451 Get It

Whereas VHL inactivation is a primary event in clear cell renal cell carcinoma (ccRCC), the precise mechanism(s) of how this interacts with the secondary mutations in tumor suppressor genes, including PBRM1 , KDM5C / JARID1C , SETD2 , and/or BAP1 , remains unclear. Gene expression analyses reveal that VHL, PBRM1, or KDM5C share a common regulation of interferon response expression signature. Loss of HIF2α, PBRM1, or KDM5C in VHL-/- cells reduces the expression of interferon stimulated gene factor 3 (ISGF3), a transcription factor that regulates the interferon signature. Moreover, loss of SETD2 or BAP1 also reduces the ISGF3 level. Finally, ISGF3 is strongly tumor-suppressive in a xenograft model as its loss significantly enhances tumor growth. Conversely, reactivation of ISGF3 retards tumor growth by PBRM1-deficient ccRCC cells. Thus after VHL inactivation, HIF induces ISGF3, which is reversed by the loss of secondary tumor suppressors, suggesting that this is a key negative feedback loop in ccRCC.
Emerging Complications Following Alternative Reservoir Placement during Inflatable Penile Prosthesis Placement: A 5-Year Multi-Institutional Experience
Hernandez, J. Clavell, Trost, Landon , Köhler, Tobias , Ring, Josh, Traweek, Raymond, Alom, Manaf, Wang, Run

Mayo Clinic

Journal of Urology | October 24, 2018 | Volume: 201 | Issue: 3 | Pages: 581-586

10.1016/j.juro.2018.10.013 | PMID 30366022 Get It

O5‐05‐01: A CRISPR/CAS9 BASED STRATEGY TO ATTENUATE THE β‐AMYLOID PATHWAY
Sun, Jichao , Shen, Minjie , Wang, Lina , Loi, Jon, Petersen, Andrew J. , Delenclos, Marion , Carlson-Stevermer, Jared , Das, Utpal , Loi, Jonathan , Stockton, Michael E. , McLean, Pamela J. , Bhattacharyya, Anita , Jones, Mathew V. , Zhao, Xinyu , Saha, Krishanu , Roy, Subhojit

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_31 | Pages: No page available

10.1016/j.jalz.2018.06.3019 Get It

O4‐02‐01: SOLUBLE TREM2 MODULATES MICROGLIAL FUNCTION AND PROTECTS AGAINST AMYLOID PATHOLOGY
Chen, Xiao‐Fen , Zhong, Li, Wang, Tingting , Wang, Zongqi , Bu, Guojun

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_26 | Pages: No page available

10.1016/j.jalz.2018.06.2915 Get It

O3‐13‐03: THE RELATIONSHIP BETWEEN TAU PET AND OTHER AD BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE
Christensen, Jon, Dincer, Aylin , Keefe, Sarah , Wang, Guoqiao , Raichle, Marcus E. , Koeppe, Bob, Network, Dominantly Inherited Alzheimer's, Gordon, Brian A. , Blazey, Tyler , Flores, Shaney , McDade, Eric , Jack, Clifford R. , Morris, John C. , Bateman, Randall J. , Benzinger, Tammie L.S. , Network, Dominantly Inherited Alzheimer's

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_19 | Pages: No page available

10.1016/j.jalz.2018.06.2845 Get It

O3‐06‐02: POLYGENIC SCORE ANALYSIS OF EXONIC VARIANTS IN AN IMMUNE CO‐REGULATORY NETWORK IDENTIFIES NOVEL PROTEIN‐ALTERING VARIANTS THAT ASSOCIATE WITH ALZHEIMER'S DISEASE
Reddy, Joseph S. , Allen, Mariet , Wang, Xue , Gregory, Jenkins D., Toral, Shastri M., Sarangi, Vivekananda , Asmann, Yan W. , Carrasquillo, Minerva M. , Ren, Yingxue , Younkin, Curtis, Rademakers, Rosa , Ertekin‐Taner, Nilüfer , Younkin, Steven G. , Biernacka, Joanna M. , McDonnell, Shannon K. , Sinnwell, Jason P. , Carrasquillo, Minerva M. , Pottier, Cyril , Ross, Owen A.

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_19 | Pages: No page available

10.1016/j.jalz.2018.06.2801 Get It

P4‐049: IDENTIFICATION OF CELL‐SPECIFIC DIFFERENTIALLY EXPRESSED GENES IN ALZHEIMER'S DISEASE
Wang, Xue , Allen, Mariet , Carrasquillo, Minerva M. , Li, Shaoyu , Asmann, Yan W. , Ertekin‐Taner, Nilüfer , Carrasquillo, Minerva M. , Burgess, Jeremy D.

Mayo Clinic

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_27 | Pages: No page available

10.1016/j.jalz.2018.06.2451 Get It